Akero Therapeutics, Inc (AKRO)

Etorro trading 970x250

About Akero Therapeutics, Inc

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California. Address: 601 Gateway Boulevard, South San Francisco, CA, United States, 94080

Akero Therapeutics, Inc News and around…

Latest news about Akero Therapeutics, Inc (AKRO) common stock and company :

Akero Therapeutics’ NASH Treatment Gets Fast Track Designation; Shares Rise
20 Oct, 2021 Yahoo! Finance

Akero Therapeutics (AKRO) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its non-alcoholic steatohepatitis (NASH) treatment, efruxifermin. Following the news, shares of AKRO rose 5.7% in the extended trading session on Tuesday. The stock was trading 9.6% higher, at the time of writing, in early trade on Wednesday. The California-based biotechnology company is engaged in the development of transformational treatments for NASH and other serious met

The Daily Biotech Pulse: Novavax Retreats Amid Vaccine Issues, LumiraDx COVID Test Approved In India, Sesen Shines On Positive Bladder Cancer Review
20 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Novavax Shares React to ...

12 Health Care Stocks Moving In Tuesday's After-Market Session
19 Oct, 2021 FinancialContent

Gainers Sesen Bio (NASDAQ:SESN) stock moved upwards by 17.82% to $1.19 during Tuesday's after-market session. This security traded ...

Akero Therapeutics Receives FDA Fast Track Designation for Efruxifermin (EFX) for the Treatment of NASH
19 Oct, 2021 Yahoo! Finance

SOUTH SAN FRANCISCO, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead program investigating efruxifermin (EFX) for the treatment of non-alcoholic steatohepatitis (NASH). The Fast Track designation facilitates the development of new drugs to

Akero Therapeutics to Present at the H.C. Wainwright 5th Annual NASH Investor Conference
05 Oct, 2021 Yahoo! Finance

SOUTH SAN FRANCISCO, Calif., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (NASH), today announced that Tim Rolph, Akero’s Chief Scientific Officer and Co-Founder, will present at the H.C. Wainwright 5th Annual NASH Investor Conference on Tuesday, October 12, 2021 at 12:00 p.m. (ET). A live webcast of the Company presentation will be available through the

Analysts Forecast 18% Upside For IWN
04 Oct, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Russell 2000 Value ETF (IWN), we found that the implied analyst target price for the ETF based upon its underlying holdings is $192.86 per unit.

Here's Why We're Not Too Worried About Akero Therapeutics' (NASDAQ:AKRO) Cash Burn Situation
08 Sep, 2021 Yahoo! Finance

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Akero Therapeutics to Present at the Morgan Stanley Virtual Global Healthcare Conference
07 Sep, 2021 FinancialContent
Implied PBSM Analyst Target Price: $45
01 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco PureBeta MSCI USA Small Cap ETF (PBSM), we found that the implied analyst target price for the ETF based upon its underlying holdings is $45.49 per unit.

The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO
13 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Akero Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business Update
13 Aug, 2021 FinancialContent
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
12 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering
11 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Stocks That Hit 52-Week Lows On Tuesday
10 Aug, 2021 FinancialContent

Before 10 a.m. ET on Tuesday, 60 companies set new 52-week lows. Key Facts: PACCAR (NASDAQ:PCAR) was the ...

The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts
10 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO
06 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Stocks That Hit 52-Week Lows On Thursday
05 Aug, 2021 FinancialContent

During Thursday's morning session, 77 companies made new 52-week lows. Areas of Interest: The largest ...

The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
05 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Fate Therapeutics Appoints Yuan Xu to its Board of Directors
04 Aug, 2021 FinancialContent
The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings
04 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Notable Wednesday Option Activity: NET, AKRO, ALKS
28 Jul, 2021 FinancialContent

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in CloudFlare Inc (NET), where a total volume of 12,928 contracts has been traded thus far today, a contract volume which is representative of approximately 1.3 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 55.8% of NET's average daily trading volume over the past month, of 2.3 million shares..

The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
28 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Oversold Conditions For Akero Therapeutics
26 Jul, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study
16 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs
15 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Akero Therapeutics Appoints Judy Chou, Ph.D., to its Board of Directors
14 Jul, 2021 FinancialContent
The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO
09 Jul, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Akero's NASH Candidate Shows Substantial Liver Fat Reductions After Four Months Of Treatment
08 Jul, 2021 FinancialContent

Akero Therapeutics Inc(NASDAQ: AKRO) has announced full results of the main portion of its Phase 2a BALANCED trial of ...

Study Published in Nature Medicine Shows Investigational NASH Drug Reduced Liver Fat to Normal Levels and Reversed Fibrosis After 16 Weeks of Treatment
08 Jul, 2021 FinancialContent

Efruxifermin (EFX) also improved markers of liver injury, inflammation, lipoproteins, and glycemic control

Relative Strength Alert For Akero Therapeutics
30 Jun, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

Akero Therapeutics, Inc (AKRO) is a NASDAQ Common Stock listed in , ,

970x250